Successfully launching Sandoz as the global leader in generic and biosimilar medicines
The first summary covers the Sandoz SABRE EMEA awards submissions across three categories:
- DACH geographic area
- Global Programme: Multiple markets in multiple regions, led from EMEA
- Pharmaceutical: Rx
The second summary covers Sandoz' entries for the following categories
- Executive communications
- Corporate media relations
In summary
2023 was an exceptional year for Sandoz, Europe's largest generic and biosimilar medicines company and one of the pharmaceutical industry's most storied brands. Sandoz' USD 11.2bn spin-off from Novartis in October was one of the most closely watched European business stories of 2023,...